Alternate-Site Glucose Test Developers Share Clinical Experience With FDA
This article was originally published in The Gray Sheet
Executive Summary
TheraSense will present clinical data related to its FreeStyle alternate-site blood glucose monitoring system to FDA's Center for Devices and Radiological Health Oct. 19 to help the agency consider labeling options for such devices.